PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The Hippo signaling pathway: a potential therapeutic target is reversed by a Chinese patent drug in rats with diabetic retinopathy.

Abstract The Hippo signaling pathway is reported to be involved in angiogenesis, but the roles of the Hippo pathway in diabetic retinopathy have not been addressed. Fufang Xueshuantong Capsule has been used to treat diabetic retinopathy in China; however, the effect of Fufang Xueshuantong Capsule on the Hippo pathway has not been investigated.
PMID
Related Publications

The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.

YAP/TAZ for cancer therapy: opportunities and challenges (review).

Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).

Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein.

A combination of the main constituents of Fufang Xueshuantong Capsules shows protective effects against streptozotocin-induced retinal lesions in rats.

Authors

Mayor MeshTerms
Keywords

Chinese medicine

Diabetic retinopathy

Hippo

Journal Title bmc complementary and alternative medicine
Publication Year Start




PMID- 28372586
OWN - NLM
STAT- MEDLINE
DA  - 20170404
DCOM- 20170417
LR  - 20170417
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 04
TI  - The Hippo signaling pathway: a potential therapeutic target is reversed by a
      Chinese patent drug in rats with diabetic retinopathy.
PG  - 187
LID - 10.1186/s12906-017-1678-3 [doi]
AB  - BACKGROUND: The Hippo signaling pathway is reported to be involved in
      angiogenesis, but the roles of the Hippo pathway in diabetic retinopathy have not
      been addressed. Fufang Xueshuantong Capsule has been used to treat diabetic
      retinopathy in China; however, the effect of Fufang Xueshuantong Capsule on the
      Hippo pathway has not been investigated. METHODS: In this study, diabetes was
      induced in Sprague-Dawley rats with intraperitoneal injection of streptozotocin. 
      Twenty weeks later, Fufang Xueshuantong Capsule was administered for 12 weeks.
      When the administration ended, the eyes were isolated for western blot and
      immunohistochemistry analyses. The levels of P- mammalian sterile 20-like (MST), 
      large tumor suppressor homolog (Lats), P- yes-associated protein (YAP),
      transcriptional co-activator with PDZ binding motif (TAZ) and TEA domain family
      members (TEAD) were measured. RESULTS: Diabetic rats had a decreased P-MST level 
      in the inner plexiform layer and reduced expression of P-YAP in the photoreceptor
      layers of their eyes. In addition, diabetic rats displayed remarkable increases
      in Lats, TAZ and TEAD in their retinas. Furthermore, Fufang Xueshuantong Capsule 
      restored the changes in the Hippo pathway. CONCLUSIONS: The Hippo signaling
      pathway is important for the progression of diabetic retinopathy and will
      hopefully be a targeted therapeutic approach for the prevention of diabetic
      retinopathy.
FAU - Hao, Gai-Mei
AU  - Hao GM
AD  - College of Basic Medicine, Key Laboratory of Ministry of Education (Syndromes and
      formulas), Key Laboratory of Beijing (Syndromes and formulas), Beijing University
      of Chinese medicine, Beijing, China.
AD  - Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Lv, Tian-Tian
AU  - Lv TT
AD  - College of Basic Medicine, Key Laboratory of Ministry of Education (Syndromes and
      formulas), Key Laboratory of Beijing (Syndromes and formulas), Beijing University
      of Chinese medicine, Beijing, China.
FAU - Wu, Yan
AU  - Wu Y
AD  - Institute of Chinese Medicine, Beijing University of Chinese medicine, Beijing,
      China.
FAU - Wang, Hong-Liang
AU  - Wang HL
AD  - College of Basic Medicine, Key Laboratory of Ministry of Education (Syndromes and
      formulas), Key Laboratory of Beijing (Syndromes and formulas), Beijing University
      of Chinese medicine, Beijing, China.
FAU - Xing, Wei
AU  - Xing W
AD  - College of Basic Medicine, Key Laboratory of Ministry of Education (Syndromes and
      formulas), Key Laboratory of Beijing (Syndromes and formulas), Beijing University
      of Chinese medicine, Beijing, China.
FAU - Wang, Yong
AU  - Wang Y
AD  - College of Basic Medicine, Key Laboratory of Ministry of Education (Syndromes and
      formulas), Key Laboratory of Beijing (Syndromes and formulas), Beijing University
      of Chinese medicine, Beijing, China.
FAU - Li, Chun
AU  - Li C
AD  - Modern Research Center for Traditional Chinese Medicine, Beijing University of
      Chinese Medicine, Beijing, China.
FAU - Zhang, Zi-Jian
AU  - Zhang ZJ
AD  - Institute of Chinese Medicine, Beijing University of Chinese medicine, Beijing,
      China.
FAU - Wang, Zheng-Lin
AU  - Wang ZL
AD  - College of Basic Medicine, Key Laboratory of Ministry of Education (Syndromes and
      formulas), Key Laboratory of Beijing (Syndromes and formulas), Beijing University
      of Chinese medicine, Beijing, China.
FAU - Wang, Wei
AU  - Wang W
AD  - College of Basic Medicine, Key Laboratory of Ministry of Education (Syndromes and
      formulas), Key Laboratory of Beijing (Syndromes and formulas), Beijing University
      of Chinese medicine, Beijing, China. [email protected]
FAU - Han, Jing
AU  - Han J
AD  - Institute of Chinese Medicine, Beijing University of Chinese medicine, Beijing,
      China. [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170404
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Drugs, Chinese Herbal)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - China
MH  - Diabetic Retinopathy/*drug therapy/genetics/metabolism
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Humans
MH  - Male
MH  - Patents as Topic
MH  - Protein-Serine-Threonine Kinases/genetics/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction/*drug effects
PMC - PMC5379696
OTO - NOTNLM
OT  - Chinese medicine
OT  - Diabetic retinopathy
OT  - Hippo
EDAT- 2017/04/05 06:00
MHDA- 2017/04/18 06:00
CRDT- 2017/04/05 06:00
PHST- 2016/09/14 [received]
PHST- 2017/03/11 [accepted]
AID - 10.1186/s12906-017-1678-3 [doi]
AID - 10.1186/s12906-017-1678-3 [pii]
PST - epublish
SO  - BMC Complement Altern Med. 2017 Apr 4;17(1):187. doi: 10.1186/s12906-017-1678-3.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>